Union Health Ministry Brings Pregabalin Under Schedule H1 to Strengthen Regulation and Prevent Misuse

1. At a Glance

• Pregabalin, a prescription drug for chronic pain, neuropathies, fibromyalgia and neurological conditions, has been moved from Schedule H to the stricter Schedule H1 of the Drugs and Cosmetics Rules, 1945 [S1].
• Relevant for UPSC: intersection of drug regulation (GS-II), public health / substance abuse (GS-II & GS-III) and federal implementation of central health laws.

2. Why in the News

• Union Ministry of Health & Family Welfare notified the inclusion via Gazette Notification G.S.R. 377(E) dated 13 May 2026, published in the Gazette of India Extraordinary on 20 May 2026 [S1].
• Triggered by State reports of misuse and abuse — particularly among youth — for the drug's sedative, euphoric and dissociative effects, plus seizures of illegally stocked stocks [S1].

3. Background & Evolution

• Drugs and Cosmetics Act, 1940 and Rules, 1945 constitute the parent regulatory framework for drug manufacture, sale and distribution [S3].
• Schedule H1 was newly created through Gazette Notification GSR 588(E) dated 30 August 2013, in force from 1 March 2014 [S2].
• Original Schedule H1 had 46 drugs — covering 3rd & 4th generation antibiotics, anti-TB drugs and habit-forming drugs — to curb OTC dispensing and antimicrobial resistance [S2].
• Pregabalin had earlier been regulated under Schedule H (prescription only, but no separate register). The 2026 notification upgrades it to Schedule H1 [S1].

4. Core Static Facts

• Drug: Pregabalin — analogue of GABA; uses: neuropathic pain, fibromyalgia, partial-onset seizures, generalized anxiety [S1].
• Implementing Ministry: Ministry of Health and Family Welfare; regulator — CDSCO (Central Drugs Standard Control Organisation) under DGHS.
• Enabling Law: Drugs and Cosmetics Act, 1940 + Drugs and Cosmetics Rules, 1945 [S1][S3].
• Notification: G.S.R. 377(E), 13 May 2026 [S1].
• Schedule H1 mandates [S1][S2]:
• Sale only on prescription of a Registered Medical Practitioner (RMP).
• Separate register at retail recording prescriber, patient, drug, quantity — to be kept for 3 years and open to inspection.
• Prominent "Schedule H1 Drug Warning" label on packaging with red border.
• Penal action under Drugs and Cosmetics Act, 1940.

5. Multi-Dimensional Analysis

Social / Public Health - Curtails diversion of a psychotropic-like analgesic that has fuelled substance abuse among youth, notably in border States [S1]. - Strengthens prescription monitoring and supply-chain accountability [S1].

Legal / Regulatory - Operationalised through delegated legislation under the Drugs and Cosmetics Act, 1940, not the NDPS Act, 1985 — keeping it a therapeutic regulation rather than a narcotics offence regime [S1]. - Violations attract penalties under the parent Act [S1].

Administrative / Federalism - Centre notifies the Schedule; State Drug Controllers enforce inspections and licensing of retailers — classic cooperative-federalism implementation gap. - States flagged misuse first, triggering Centre's action [S1].

Scientific / Pharmacological - Pregabalin is a gabapentinoid; misused for euphoric/dissociative effects, often potentiating opioids — already a controlled substance in UK, US. - Schedule H1 introduced in 2014 also targeted antimicrobial resistance (AMR) by restricting 3rd–4th gen antibiotics [S2].

6. Recent Developments (last 12-18 months)

• 20 May 2026 — Gazette of India Extraordinary publishes G.S.R. 377(E) [S1].
• 22 May 2026 — PIB release by MoHFW announcing the reclassification [S1].
• Continued PIB releases on AMR & antibiotic stewardship, of which Schedule H1 remains a core tool [S2].

7. Prelims Hooks

• Schedule H1 was inserted via GSR 588(E) dated 30 August 2013, in force 1 March 2014 [S2].
• Original Schedule H1 listed 46 drugs including 3rd/4th-gen antibiotics, anti-TB drugs and habit-forming drugs [S2].
• Schedule H1 register must be retained for 3 years [S2].
• Pregabalin notification: G.S.R. 377(E), 13 May 2026 [S1].
• Pregabalin earlier sat under Schedule H (not Schedule X) [S1].
• Parent statute: Drugs and Cosmetics Act, 1940 and Rules, 1945 [S1][S3].
• Pregabalin is approved for chronic pain, neuropathies, fibromyalgia and certain neurological conditions [S1].
• Drug regulator is CDSCO under MoHFW; State Drug Controllers enforce at retail.
• Schedule X drugs (psychotropics like amphetamines) require licences + 2-year prescription retention — distinct from H1.
• Drugs covered by NDPS Act, 1985 are separate from D&C Act Schedules.
• Schedule H1 warning label must have a red box with the caution text.
• Pregabalin is an analogue of GABA (gabapentinoid class).

8. Mains Relevance

• GS-II: Government policies for health sector; issues relating to development and management of Social Sector (Health). Role of regulatory bodies (CDSCO).
• GS-III: Internal security — drug abuse and trafficking (linkage with youth substance abuse).
• Possible question stems: 1. "Reclassification of drugs under Schedule H1 reflects the state's calibrated response to substance abuse without resorting to criminalisation. Discuss with reference to Pregabalin." 2. "Examine the institutional architecture of pharmaceutical regulation in India. How does cooperative federalism shape its enforcement?" 3. "Substance abuse among Indian youth is increasingly driven by legal prescription drugs. Critically analyse."

9. Related Topics to Study Next

• NDPS Act, 1985 — comparative regulation of psychotropic substances.
• Drugs and Cosmetics (Amendment) Bills & proposed New Drugs, Medical Devices and Cosmetics Bill — overhaul of 1940 Act.
• Antimicrobial Resistance (AMR) National Action Plan — original rationale of Schedule H1 [S2].
• CDSCO & State Drug Controllers — institutional architecture.
• Nasha Mukt Bharat Abhiyaan — demand-side response to drug abuse.
• Jan Aushadhi / PMBJP — generic drug access vs regulation trade-offs.
• e-Pharmacy regulation — diversion risk in online sales.
• Pharmacy Act, 1948 — role of registered pharmacists in prescription compliance.

10. Common Errors / Trap Areas

• Confusing Schedule H (RMP prescription only) with Schedule H1 (RMP + separate register + warning label) and Schedule X (psychotropics; licence + duplicate prescription).
• Assuming Pregabalin is now under NDPS Act — it is NOT; it remains under D&C Act [S1].
• Wrong ministry: regulation sits with MoHFW/CDSCO, not Ministry of Chemicals & Fertilizers (which handles pharma industry/pricing via NPPA).
• Year mix-up: Schedule H1 was created in 2013 (in force 2014) [S2] — not in 2026 (only Pregabalin's inclusion is 2026).
• Treating Schedule H1 as an antibiotics-only schedule — it always included habit-forming drugs and anti-TB drugs too [S2].

11. Sources

• [S1] Union Health Ministry Brings Pregabalin Under Schedule H1 to Strengthen Regulation and Prevent Misuse — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2263975 — (tier: 1)
• [S2] Rules for Selling of Drugs Under Schedule H1 (PIB) — https://www.pib.gov.in/newsite/PrintRelease.aspx?relid=101251 — (tier: 1)
• [S3] Drugs and Cosmetics Act, 1940 and Rules, 1945 (India Code) — https://upload.indiacode.nic.in/showfile?actid=AC_CEN_12_13_00023_194023_1523353460112&type=rule&filename=Drugs+and+Cosmetics+Act%2C+1940+and+Rules%2C+1945.pdf — (tier: 1)